WO2005063051A1 - Mikronährstoffkombinationsprodukt geeignet zur ergänzenden bilanzierten diät bei altersbedingter makuladegeneration - Google Patents
Mikronährstoffkombinationsprodukt geeignet zur ergänzenden bilanzierten diät bei altersbedingter makuladegeneration Download PDFInfo
- Publication number
- WO2005063051A1 WO2005063051A1 PCT/EP2004/053579 EP2004053579W WO2005063051A1 WO 2005063051 A1 WO2005063051 A1 WO 2005063051A1 EP 2004053579 W EP2004053579 W EP 2004053579W WO 2005063051 A1 WO2005063051 A1 WO 2005063051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination product
- weight
- micronutrient combination
- vitamin
- micronutrient
- Prior art date
Links
- 239000013066 combination product Substances 0.000 title claims abstract description 84
- 229940127555 combination product Drugs 0.000 title claims abstract description 84
- 239000011785 micronutrient Substances 0.000 title claims abstract description 79
- 235000013369 micronutrients Nutrition 0.000 title claims abstract description 79
- 206010064930 age-related macular degeneration Diseases 0.000 title claims description 16
- 208000002780 macular degeneration Diseases 0.000 title claims description 13
- 235000005911 diet Nutrition 0.000 title claims description 9
- 230000000378 dietary effect Effects 0.000 title claims description 8
- 235000015872 dietary supplement Nutrition 0.000 title 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 63
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 56
- 239000011701 zinc Substances 0.000 claims abstract description 32
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 32
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims abstract description 29
- 235000012680 lutein Nutrition 0.000 claims abstract description 29
- 229960005375 lutein Drugs 0.000 claims abstract description 29
- 239000001656 lutein Substances 0.000 claims abstract description 29
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 29
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 29
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 29
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000010949 copper Substances 0.000 claims abstract description 26
- 229910052802 copper Inorganic materials 0.000 claims abstract description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 42
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 34
- 235000016804 zinc Nutrition 0.000 claims description 31
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 27
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 27
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 27
- 235000010930 zeaxanthin Nutrition 0.000 claims description 27
- 239000001775 zeaxanthin Substances 0.000 claims description 27
- 229940043269 zeaxanthin Drugs 0.000 claims description 27
- 229940108928 copper Drugs 0.000 claims description 25
- 235000019154 vitamin C Nutrition 0.000 claims description 19
- 239000011718 vitamin C Substances 0.000 claims description 19
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 18
- 229930003268 Vitamin C Natural products 0.000 claims description 18
- 235000019165 vitamin E Nutrition 0.000 claims description 18
- 239000011709 vitamin E Substances 0.000 claims description 18
- 229930003427 Vitamin E Natural products 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 229940046009 vitamin E Drugs 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 235000004251 balanced diet Nutrition 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 235000010980 cellulose Nutrition 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 235000011478 zinc gluconate Nutrition 0.000 claims description 9
- 239000011670 zinc gluconate Substances 0.000 claims description 9
- 229960000306 zinc gluconate Drugs 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000007941 film coated tablet Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 235000012222 talc Nutrition 0.000 claims description 6
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000010215 titanium dioxide Nutrition 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 241000978776 Senegalia senegal Species 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000008298 dragée Substances 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 235000019856 cupric gluconate Nutrition 0.000 claims description 3
- 239000011642 cupric gluconate Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- 235000012241 calcium silicate Nutrition 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims 1
- 238000012937 correction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000010445 mica Substances 0.000 claims 1
- 229910052618 mica group Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 abstract description 2
- 206010025421 Macule Diseases 0.000 description 15
- 235000021466 carotenoid Nutrition 0.000 description 13
- 150000001747 carotenoids Chemical class 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 7
- 235000013619 trace mineral Nutrition 0.000 description 7
- 239000011573 trace mineral Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000007888 film coating Substances 0.000 description 5
- 238000009501 film coating Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000002966 varnish Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012730 carminic acid Nutrition 0.000 description 2
- 239000004106 carminic acid Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 206010010957 Copper deficiency Diseases 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DGQLVPJVXFOQEV-NGOCYOHBSA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-NGOCYOHBSA-N 0.000 description 1
- 229940114118 carminic acid Drugs 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000021112 essential micronutrients Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 230000004483 macular pigment optical density Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a mifaonutrient combination product.
- the micronutrient combination product can be used, for example, for the supplementary balanced diet in the case of age-related macular degeneration.
- Carotenoids lutein and zeaxanthin as well as the trace element zinc are decisively involved.
- the system offers optimal protection only if all of its active components are available in sufficient quantities.
- the eye is exposed to oxidative stress to an increased degree due to the visual process and the constant exposure to light. It therefore has an increased need for an adequate supply of the antioxidant substances vitamin C, vitamin E, zinc and the vitamin-like carotenoids lutein and zeaxanthin.
- the organs that require a particularly high concentration of the carotenoids lutein and zeaxanthin include the macula of the eye.
- the medical term "macula lutea” is to be understood as the center of the retina, ie the point of sharpest vision. This is where the most sensitive visual cells of the eye are located.
- the vitamin preparations known in the prior art contain various, often high-dose, compositions of vitamins and trace elements, which, however, are not aimed at supplying the macula of the eye. Most of these compositions contain high levels of antioxidant vitamins and trace elements, but not lutein and zeaxanthin. A disadvantage of these preparations is their lack of consideration of the macula, which has a central function in the visual process.
- antioxidant preparations Another disadvantage of commercially available antioxidant preparations is that the age-dependent vitamin and mineral requirements are not taken into account enough. Deficiency symptoms due to undersupply due to malnutrition or malnutrition or illness can quickly become noticeable in old age in particular with regard to diseases such as AMD, which are not adequately taken into account by means of coordinated preparations.
- micronutrient combination product comprising zeaxanthin, lutein, zinc and copper. It has surprisingly been shown that the macula has been significantly strengthened by the optimized combination of the vitamin-like carotenoids lutein and zeaxanthin. It has also surprisingly been found that the vitamin-like carotenoids used in an optimized manner according to the invention, by virtue of their ability to trap existing radicals, bring about improved preventive protection of the macula.
- vitamin-like carotenoids lutein and zeaxanthin accumulate selectively in high concentrations in the macula and thus protect this area by filtering the light and trapping the harmful "free radicals".
- the targeted supply These essential micronutrients can therefore help protect the eye from the development of age-related macular degeneration or slow its progression.
- micronary combination product according to the invention Another great advantage of the micronary combination product according to the invention is realized in that lutein can bring about an increase in the macular pigment density.
- micronutrient combination product according to the invention has copper, which counteracts a possible copper deficiency which can result from the intake of zinc. It is advantageous that the invention
- Mfconutrient combination product due to the low zinc content according to the invention and the resulting significant reduction in side effects caused by zinc, comprises an extremely low dose of copper.
- Micronutrient combination product is available that provides a comprehensive and balanced supply of the macula. It continues through each other coordinated administration of the carotenoids and trace elements safely prevents overdosing and provides a coordinated supply
- the mtoonutrient combination product according to the invention can be used for a supplementary balanced diet or for accompanying administration, for example in the treatment of age-related macular degeneration.
- the micronutrient combination product based on the total weight of the micronutrient combination product, has the active ingredients: a. 0.5% by weight to 5% by weight, preferably 0.75% by weight to 2.5% by weight, particularly preferably 0.8% by weight to 1.2% by weight, lutein; b. 0.01% by weight to 0.1% by weight, preferably 0.02% by weight to 0.08% by weight, particularly preferably 0.04% by weight to 0.06% by weight, zeaxanthin ; c. 0.005% by weight to 0.1% by weight, preferably 0.01% by weight to 0.08% by weight, particularly preferably 0.015% by weight to 0.05% by weight, copper; d. 0.5% by weight to 5% by weight, preferably 1% by weight to 2.5% by weight, particularly preferably 1.3% by weight to 2% by weight, zinc
- micronutrients are the substances which the micronutrient combination product has, preferably selected from the group comprising zeaxanthin, lutein, zinc, copper, vitamin E and / or vitamin C.
- the micronutrient combination product advantageously has at least one vitamin, preferably vitamin C and / or vitamin E.
- the mtoonutrient combination ion product based on the total weight of the micronutrient combination ion product, has 5% by weight to 30% by weight, preferably 10% by weight to 20% by weight, particularly preferably 10% by weight to 15% by weight % Vitamin C and / or 0.5% by weight to 3% by weight, preferably 1% by weight to 2% by weight, particularly preferably 1.0% by weight to 1.5% by weight, of vitamin E.
- the micronutrient combination product has lutein, zeaxanthin, zinc, copper, vitamin C and vitamin E.
- the micronutrient combination product based on the total weight of the micronutrient combination product, comprises the active ingredients: a. 1 wt% lutein; b. 0.05 wt% zeaxanthin c. 12.5% by weight of vitamin C; d. 1.25% by weight of vitamin E; e. 0.033% by weight copper; f. 1.67% by weight zinc.
- Suitable salts are selected, for example, from the group comprising sulfates and / or oxides.
- zinc and copper are in the form of zinc gluconate and copper (II) gluconate.
- the use of zinc gluconate and copper (II) gluconate advantageously improves the bioavailability.
- Zinc gluconate shows better absorption than the commonly used zinc oxide. Zinc gluconate can also show better absorption than zinc sulfate. This increased bioavailability enables a much smaller amount of zinc to be used as a daily dose or as a single dose, thereby reducing the risk of
- Zinc gluconate in particular shows a significantly better absorption than the frequently used zinc oxide.
- the supply of zinc to the macula is believed to be improved by using zinc gluconate. It is it is also conceivable that the necessary amount of zinc of the micronutrient combination product can be reduced by the use of the readily absorbable zinc gluconate, and thus a possible overdosing can be avoided.
- the mücronutrient combination product which is optimally formulated with regard to its constituents, based on a daily dose of the micronutrient combination product, comprises the active ingredients: a. 2 mg to 40 mg, preferably 6 mg to 24 mg, lutein; b. 0.1 mg to 2 mg, preferably 0.3 mg to 1.2 mg, zeaxanthin; c. 50 mg to 500 mg, preferably 75 mg to 300 mg, vitamin C; d. 2 mg to 60 mg, preferably 7.5 mg to 30 mg, vitamin E; e. 0.02 mg to 2 mg, preferably 0.2 mg to 0.8 mg, copper; f. 1 mg to 80 mg, preferably 10 mg to 40 mg, zinc.
- active ingredients a. 2 mg to 40 mg, preferably 6 mg to 24 mg, lutein; b. 0.1 mg to 2 mg, preferably 0.3 mg to 1.2 mg, zeaxanthin; c. 50 mg to 500 mg, preferably 75 mg to 300 mg, vitamin C; d. 2 mg to 60 mg, preferably
- the micronutrient combination product according to the invention has zeaxanthin, which, in a balanced combination with lutein, the trace elements zinc and copper and other vilamines with an antioxidative effect, through a balanced supply of the macula to prevent radical damage to the effect of the agent according to the invention contributes, which has a positive influence on the improvement of vision in old age and the development of age-related macular degeneration is made more difficult. It has surprisingly been found that in particular the use of zeaxanthine in accordance with the invention combined with zinc has a positive effect on the supply to consumers compared to the use of monopreparations.
- the use of vilamin-like carotenoids with antioxidant properties together with zinc and copper in accordance with the invention shows that
- Micronutrient combination product has an improved nutritional or dietary effect.
- the advantageous properties result from the optimized selection of the individual components, which were specifically selected to combat oxidative damage to the macula by radicals and compensate for a deficit in antioxidants caused by nutritional deficits or risk factors such as smoking and alcohol consumption, environmental pollution, stress or UV radiation ,
- Another advantage of the nutrient combination product according to the invention is the synergistic effect with regard to a comprehensive holistic care of the macula.
- the macula is strengthened by the optimized combination of vitamins and trace elements, especially the vitamins carotenoids lutein and zeaxanthin and zinc and copper.
- the dosages of the agent according to the invention do not cause any damaging side effects and can be used for prophylaxis and to compensate for an existing deficiency in the macula.
- This is advantageous for the supplementary balanced diet as well as for the dietary treatment for age-related macular degeneration.
- a positive effect is shown in particular by a supplementary balanced diet or dietary administration in deficiency states and the prevention of the development of a deficiency situation that can lead to age-related macular degeneration.
- Embodiments of the mifaonutrient combination product which contain no further carotenoids may be suitable. Administration of additional carotenoids can have an adverse effect on absorption and / or cause a possible interaction of the carotenoids.
- an embodiment of the combination product that is free of beta-Caroline and / or copper oxide may be suitable according to the invention
- Ingestion of beta-carotene can lead to damage in connection with medicines, especially in smokers in high doses.
- the micronutrient combination product of the invention can be free of beta-carotene.
- An embodiment of the micronutrient combination product, which is free of beta-carotene, advantageously creates the possibility of being able to be taken by smokers as well.
- the micronutrient combination product can be in solid, liquid and / or gel form; the micronutrient combination product is preferably in preparation forms selected from the group comprising tablets, film-coated tablets, dragées, capsules, powder, granules, solutions and / or effervescent tablets with the same or different compositions ,
- the micronutrient combination product is in a solid dosage form, the core of the dosage form being 200 mg to 1000 mg, preferably 400 mg to 800 mg, and preferably 600 mg.
- the core of the dosage form can preferably be coated with a film coating.
- the dosage forms can be produced by the generally customary methods.
- the micronutrient combination product according to the invention is preferably in the form of a tablet, in particular a film tablet.
- the tablet preferably comprises a tablet core which can be coated with a film coating.
- the micronutrient combination product in particular the tablet core, can have further auxiliaries, preferably selected from the group comprising lactose, povidone, cellulose and / or cellulose derivatives, microcrystalline cellulose, starch and / or Starch derivatives, magnesium stearate, stearic acid, gelatin, sodium aluminum silicate, silicon dioxide, maltodextrin, dextrose, talc, titanium dioxide, calcium carbonate, vegetable fats, tricalcium phosphate, antioxidants, stabilizers, gum arabic, calcium phosphates, calcium silicate, sucrose, sodium citrate / sodium citrate or citric acid.
- Particularly preferred auxiliaries are selected from the group comprising lactose, microcrystalline cellulose and / or magnesium stearate.
- the micronutrient combination product can have coating agents, also referred to as coating substances.
- suitable coating materials for film coating selected from the group comprising cellulose and or cellulose derivatives, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and / or microcrystalline cellulose, titanium dioxide, dyes, talc, polymethacrylates, shellac, polyvinylpolyirolidone, polyvinylpolyirolidone , Triacetin, triethyl citrate, propylene glycol, glycerol, gum arabic, silicon dioxide, glycerol monostearate and / or cottonseed oil.
- Coating materials are preferably selected from the group comprising hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, glycerol, talc, cottonseed oil, titanium dioxide and / or dyes.
- Preferred dyes are selected from the group comprising iron oxides, indigo
- AtLacke are selected from the group comprising yellow orange S AtLack and / or Chochenillerot A AI-Lack.
- the micronutrient combination product in the form of a film tablet comprising a tablet core and a film coating, comprises a film amount in the range from 1% by weight to 12% by weight, preferably 2% by weight to 10% by weight, particularly preferably 5% by weight to 8% by weight, based on the weight of the tablet core.
- the micronutrient combination product can have further additives which are compatible with the micronutrients in galenics.
- the micronutrients are preferably used in a form that can be processed for the selected dosage form.
- the micronutrient combination product preferably has vitamin E in the form of vitamin E acetate.
- the mineral nutrient combination product preferably has vitamin C in the form of granules.
- the micronutrient combination product further preferably has vitamin C in the form of ascorbic acid.
- the micronutrient combination product has zeaxanthin, lutein, zinc gluconate, copper (H) gluconate, vitamin eacetate, ascorbic acid, cellulose, lactose and / or magnesium stearate.
- the micronutrient combination product based on a daily dose of the micronutrient combination product, comprises the active ingredients: a. 12 mg lutein; b. 0.6 mg zeaxanthin; c. 150 mg vitamin C; d. 15 mg vitamin E; e. 0.4 mg copper; f. 20 mg zinc.
- the micronutrient preparation can also contain additives, accompanying substances and / or raw materials that are heavier than the actual active substances, so that the amounts given can be lower or higher, based on a daily dose or single dose.
- the MU ⁇ ronutrient combination product based on a single dose of the micronutrient combination product, comprises the active ingredients: a. 6 mg lutein; b. 0.3 mg zeaxanthin c. 75 mg vitamin C; d. 7.5 mg vitamin E; e. 0.2 mg copper; f. 10 mg zinc.
- a single dose is understood to mean an administration unit of the micronutrient combination product; a single dose of the micronutrient combination product corresponds, for example, to a tablet, a film-coated tablet, a dragee, a capsule or a single administration unit of another form of preparation, such as powder or granules.
- a daily dose is understood to mean the amount of the micronutrient combination product that is administered per day.
- the daily dose and / or single dose is preferably distributed over several identical or different preparation forms, the preparation forms being able to have the same or different active substances and or active substance weight contents.
- the micronutrient combination product can be used to produce an agent for the dietary prevention and / or treatment of eye diseases, preferably in the case of age-related macular degeneration.
- the micronutrient combination product according to the invention is furthermore suitable as an agent for a supplementary balanced diet.
- the term "dietary treatment” is explained in more detail in EU Directive 1999/21 / EC, which has been implemented as the 10th regulation to amend the diet regulation in German law since 01.01.2002 Thanks to the beneficial active ingredients of the micronutrient combination product, it can also be used as a supplement to the balanced diet, in particular food, as part of a dietary nutritional consultation.
- the micronutrient combination product can preferably be used for the supplementary balanced diet in the case of age-related macular degeneration. It has been shown that, in particular, an impending nutrient deficiency can be compensated for in older people.
- micronutrient combination ion products examples include:
- preparation forms selected from the group comprising tablets, film-coated tablets, dragees, capsules, powders, granules, solutions and / or effervescent tablets, have the customary auxiliaries used for formulating the respective preparation forms, so that in the examples only those contained are included Active ingredients can be listed.
- Micronutrient combination product comprising 1 film-coated tablet with the following active ingredients: 6 mg lutein; 0.3 mg zeaxanthin - 75 mg vitamin C; 7.5 mg vitamin E; 0.2 mg copper; 10 mg zinc.
- Micronutrient combination product daily dose comprising 2 film-coated tablets, each with the following active ingredients: 6 mg lutein; 0.3 mg zeaxanthin 75 mg vitamin C; 7.5 mg vitamin E; - 0.2 mg copper; 10 mg zinc.
- 635 mg film-coated tablet comprising the following active ingredients: 6 mg lutein; 0.3 mg zeaxanthin 75 mg vitamin C; 7.5 mg vitamin E; - 0.2 mg copper; 10 mg zinc, hypromellose, hydroxypropyl cellulose, glycerol, yellow orange varnish S, cochineal red varnish A, titanium dioxide and talc being contained as auxiliaries, and the tablet core accounting for 600 mg and the film coating 35 mg.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04817575A EP1696743A1 (de) | 2003-12-23 | 2004-12-17 | Mikronährstoffkombinationsprodukt geeignet zur ergänzen den bilanzierten diät bei altersbedingter makuladegeneration |
US10/583,953 US8883221B2 (en) | 2003-12-23 | 2004-12-17 | Micronutrient combination product for use as a dietetic food supplement in age-related macular degeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE20320101U DE20320101U1 (de) | 2003-12-23 | 2003-12-23 | Mikronährstoffkombinationsprodukt geeignet zur ergänzenden bilanzierten Diät bei altersbedingter Makuladegeneration |
DE20320101.9 | 2003-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005063051A1 true WO2005063051A1 (de) | 2005-07-14 |
Family
ID=32240734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/053579 WO2005063051A1 (de) | 2003-12-23 | 2004-12-17 | Mikronährstoffkombinationsprodukt geeignet zur ergänzenden bilanzierten diät bei altersbedingter makuladegeneration |
Country Status (5)
Country | Link |
---|---|
US (1) | US8883221B2 (de) |
EP (1) | EP1696743A1 (de) |
DE (1) | DE20320101U1 (de) |
RU (1) | RU2006120614A (de) |
WO (1) | WO2005063051A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007029008A2 (en) * | 2005-09-08 | 2007-03-15 | Dsm Ip Assets B.V. | Method of treatment or prevention of age-related macular degeneration |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202004010212U1 (de) * | 2004-06-30 | 2004-09-23 | Dr. Mann Pharma, Chem.-Pharm. Fabrik Gmbh | Lutein-enthaltende Zusammensetzung |
EP1814540A2 (de) * | 2004-11-16 | 2007-08-08 | Nu-Tein Co., Inc. | Zusammensetzungen zur behandlung von neovaskulären augenerkrankungen und maculadegeneration |
DE202007012373U1 (de) * | 2007-09-04 | 2009-01-08 | Omnivision Gmbh | Nahrungsergänzungsmittel, Beutel mit einem Nahrungsergänzungsmittel sowie Verwendung eines Nahrungsergänzungsmittels |
CN108042504A (zh) * | 2017-12-15 | 2018-05-18 | 拜尔普兰(厦门)生物药业有限公司 | 一种叶黄素片组合物及其制备方法 |
DE202021104882U1 (de) * | 2021-09-10 | 2021-09-28 | Lighthouse Pharma GmbH | Zusammensetzung und Darreichungsform |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2301775A (en) * | 1995-06-07 | 1996-12-18 | Howard Foundation | High dosage lutein and zeaxanthin for macula therapy |
EP1214893A1 (de) * | 2000-12-16 | 2002-06-19 | Aventis Pharma Deutschland GmbH | Zusammensetzungen zur Verbesserung der Gesundheit |
US20020182266A1 (en) * | 2001-03-23 | 2002-12-05 | Bartels Stephen Paul | Nutritional supplement to treat macular degeneration |
US6582721B1 (en) * | 1999-09-17 | 2003-06-24 | Alcon, Inc. | Stable carotene-xanthophyll beadlet compositions and methods of use |
WO2003063848A1 (en) * | 2002-01-30 | 2003-08-07 | Dsm Ip Assets B.V. | Lutein/zeaxanthin for glare protection |
WO2003103646A1 (en) * | 2002-06-06 | 2003-12-18 | Wyeth | Infant formula compositions containing lutein and zeaxanthin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US6914073B2 (en) * | 1999-03-18 | 2005-07-05 | Bristol Myers Squibb Company | Vitamin formulation for cardiovascular health |
US6579544B1 (en) * | 2000-05-31 | 2003-06-17 | Nutriex, L.L.C. | Method for supplementing the diet |
-
2003
- 2003-12-23 DE DE20320101U patent/DE20320101U1/de not_active Expired - Lifetime
-
2004
- 2004-12-17 RU RU2006120614/13A patent/RU2006120614A/ru unknown
- 2004-12-17 US US10/583,953 patent/US8883221B2/en active Active
- 2004-12-17 EP EP04817575A patent/EP1696743A1/de not_active Withdrawn
- 2004-12-17 WO PCT/EP2004/053579 patent/WO2005063051A1/de active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2301775A (en) * | 1995-06-07 | 1996-12-18 | Howard Foundation | High dosage lutein and zeaxanthin for macula therapy |
US6582721B1 (en) * | 1999-09-17 | 2003-06-24 | Alcon, Inc. | Stable carotene-xanthophyll beadlet compositions and methods of use |
EP1214893A1 (de) * | 2000-12-16 | 2002-06-19 | Aventis Pharma Deutschland GmbH | Zusammensetzungen zur Verbesserung der Gesundheit |
US20020182266A1 (en) * | 2001-03-23 | 2002-12-05 | Bartels Stephen Paul | Nutritional supplement to treat macular degeneration |
WO2003063848A1 (en) * | 2002-01-30 | 2003-08-07 | Dsm Ip Assets B.V. | Lutein/zeaxanthin for glare protection |
WO2003103646A1 (en) * | 2002-06-06 | 2003-12-18 | Wyeth | Infant formula compositions containing lutein and zeaxanthin |
Non-Patent Citations (1)
Title |
---|
HAMMOND B R ET AL: "DENSITY OF THE HUMAN CRYSTALLINE LENS IS RELATED TO THE MACULAR PIGMENT CAROTENOIDS, LUTEIN AND ZEAXANTHIN", July 1997, OPTOMETRY AND VISION SCIENCE, WILLIAMS AND WILKINS, BALTIMORE, MD, US, PAGE(S) 499-504, ISSN: 1040-5488, XP009011411 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007029008A2 (en) * | 2005-09-08 | 2007-03-15 | Dsm Ip Assets B.V. | Method of treatment or prevention of age-related macular degeneration |
WO2007029008A3 (en) * | 2005-09-08 | 2007-07-12 | Dsm Ip Assets Bv | Method of treatment or prevention of age-related macular degeneration |
Also Published As
Publication number | Publication date |
---|---|
US20080014287A1 (en) | 2008-01-17 |
DE20320101U1 (de) | 2004-04-29 |
RU2006120614A (ru) | 2007-12-27 |
US8883221B2 (en) | 2014-11-11 |
EP1696743A1 (de) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69907010T2 (de) | Ubichinon enthaltende zusammensetzung geeignet zur förderung des erhöhten intramitochondrialen transportes von ubichinonen und verfahren deren verwendung | |
DE60201824T2 (de) | Nahrungsergänzung zur behandlung von makuladegeneration | |
EP0755633B1 (de) | Zwei-Phasen-Präparat | |
DE202006020886U1 (de) | Algen- und Algenextrakt-Nahrungsergänzungszusammensetzung | |
EP2207435B1 (de) | Funktionsgetränk | |
DE202006014588U1 (de) | Carotinoide-enthaltendes Produkt | |
DE202007013532U1 (de) | Zusammensetzung enthaltende Phospholipide, geeignet zur Stärkung der Gehirn- und Gedächtnisfunktion | |
DE10221403A1 (de) | Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung | |
EP1696743A1 (de) | Mikronährstoffkombinationsprodukt geeignet zur ergänzen den bilanzierten diät bei altersbedingter makuladegeneration | |
DE202008016372U1 (de) | Vitamin enthaltende Zusammensetzung | |
WO2004058268A2 (de) | Verwendung von tetrahydrobiopterinderivaten zur behandlung und ernährung von patienten mit aminosäurestoffwechselstörungen | |
DE202009002126U1 (de) | Spurenelement enthaltende Zusammensetzung | |
DE4405545A1 (de) | Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation | |
EP1616490A1 (de) | Zusammensetzung enthaltend Lutein sowie Zink und Kupfer | |
DE102014119565A1 (de) | Zubereitung in Form eines Riegels | |
EP1437051B9 (de) | Ocuvite Lutein | |
DE69918152T2 (de) | Behandlung von verdauungsstörungen | |
DE202004013660U1 (de) | Vitamin-enthaltendes Produkt | |
DE202013002498U1 (de) | Futtermittelzusatz für Nutz- und Haustiere | |
DE10258129A1 (de) | Lebensmittelzubereitung | |
DE202008002263U1 (de) | Gesundheitsförderndes Mittel und dessen Verwendung | |
DE202018101715U1 (de) | Mittel zur Behandlung von neurodegenerativen Erkrankungen | |
EP0713368B1 (de) | Lagerstabile angereicherte flüssige nahrungsmittel und verfahren zu ihrer herstellung | |
DE4335441A1 (de) | Mittel zur Gesundheitsvorsorge im Herz- Kreislaufsystem beim Menschen | |
DE102008009752A1 (de) | Gesundheitsförderndes Mittel und dessen Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004817575 Country of ref document: EP Ref document number: 2006120614 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004817575 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10583953 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10583953 Country of ref document: US |